Trial Profile
A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of naldemedine in cancer patients with opioid-induced constipation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2019
Price :
$35
*
At a glance
- Drugs Naldemedine (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Acronyms COMPOSE IV
- Sponsors Shionogi
- 22 Feb 2019 According to a Shionogi media release, European Commission (EC) granted a Marketing Authorisation (MA) for Rizmoic (naldemedine), for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative, based on data from three phase 3 efficacy and safety studies (V9231, V9232 and V9236) and one long term safety study (V9235).
- 18 Dec 2018 According to a Shionogi media release, based on data from three phase 3 efficacy and safety studies (V9231, V9232 and V9236) and one long term safety study (V9235), the CHMP has adopted a positive opinion recommending Rizmoic (naldemedine), for the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. The EC will issue a decision in due course for naldemedine, taking into account the recommendation from the CHMP.
- 02 Oct 2017 Results published in the Journal of Clinical Oncology